1. Home
  2. CFND vs ITRM Comparison

CFND vs ITRM Comparison

Compare CFND & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

HOLD

Current Price

$3.72

Market Cap

27.4M

Sector

N/A

ML Signal

HOLD

Logo Iterum Therapeutics plc

ITRM

Iterum Therapeutics plc

SELL

Current Price

$0.03

Market Cap

24.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CFND
ITRM
Founded
N/A
2015
Country
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
24.3M
IPO Year
2025
2018

Fundamental Metrics

Financial Performance
Metric
CFND
ITRM
Price
$3.72
$0.03
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
17.0K
46.5M
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$947.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.55
$0.03
52 Week High
$9.67
$1.42

Technical Indicators

Market Signals
Indicator
CFND
ITRM
Relative Strength Index (RSI) 45.07 26.10
Support Level $3.62 N/A
Resistance Level $4.15 $0.39
Average True Range (ATR) 0.13 0.02
MACD 0.01 -0.01
Stochastic Oscillator 48.81 3.34

Price Performance

Historical Comparison
CFND
ITRM

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: